plaque psoriasis

The top 25 psoriasis authorsIn 2018 at just five days into the New Year, a search of PubMed revealed 86 new psoriasis studies. So, who is leading the pack?
Hard-to-treat psoriasis cases respond to secukinumabSecukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Promising new treatments for plaque psoriasisThe American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
Secukinumab safe and effective through 5 years in psoriasisPatients were continually treated with the 300 mg for five years.
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque Psoriasis
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque PsoriasisIn July, our table of the month sums up biologics approved for moderate-to-severe plaque psoriasis and common adverse events associated with these biologics.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
FDA approves etanercept biosimilar for psoriasis, psoriatic arthritisThe FDA approved the biosimilars Erelzi for plaque psoriasis and Enbrel for psoriatic arthritis.
Biologics, acetaminophen and the multimillion-dollar lawsuitAre doctors liable when patients combine acetaminophen with biologic medications used to treat psoriasis?
6 facts to know about the new psoriasis drugFDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
FDA approves ixekizumab for plaque psoriasisThe FDA approved Taltz (ixekizumab, Eli Lilly and Company) injection 80 mg/mL March 22 for treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Learn more